Protocol Ledger

NCT07324304 · Phase II · RECRUITING

NWRD06 DNA Plasmid for HCC After Curative Resection.

Interventional Phase II clinical trial protocol NCT07324304 sponsored by Newish Technology (Beijing) Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-08 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07324304
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07324304
Protocol FieldVerified Registry Value
NCT IdentifierNCT07324304
Consolidated Lead SponsorNewish Technology (Beijing) Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2025-12-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI